Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.

GK, Abou-Alfa; S, Qin; BY, Ryoo; SN, Lu; CJ, Yen; YH, Feng; HY, Lim; F, Izzo; M, Colombo; D, Sarker; L, Bolondi; G, Vaccaro; WP, Harris; Z, Chen; RA, Hubner; T, Meyer; W, Sun; JJ, Harding; EM, Hollywood; J, Ma; PJ, Wan; M, Ly; J, Bomalaski; A, Johnston; CC, Lin; Y, Chao; LT, Chen

doi:10.1093/annonc/mdy101

Public

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.

Shared by NobleBlocks on Jun 1, 2018 • 12:00 AM UTC

Authors:

Abou-Alfa GK

Qin S

Ryoo BY

Abstract

<h4>Background</h4>Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG 20 is a cloned arginine degrading enzyme-arginine deiminase-conjugated with polyethylene glycol. The goal of ...

Discussions